Merck Animal Health has announced its acquisition of TARGAN, a company specializing in high-speed gender identification and vaccine delivery for poultry. Additionally, Merck is collaborating with the Hashgraph Group to implement Hedera-powered digital product passports, enhancing supply chain traceability in line with new EU regulations. These initiatives mark Merck’s strategic move into animal health technology, aiming to bolster customer relationships through automation.
As of now, Merck’s stock is priced at $120.76, reflecting a 53% return over the past year and 81.5% over five years. Investors are encouraged to watch how these new technologies integrate and contribute to Merck’s core pharmaceutical operations, especially regarding execution speed and market rollout. Key risks include integration challenges and regulatory changes affecting the adoption of new technologies. Overall, these developments may diversify Merck’s growth story beyond oncology-focused narratives.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/merck-expands-animal-health-automation-and-traceability-with
